Vesleteplirsen clinical trials
Also written SRP-5051.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2018
How each study uses vesleteplirsen is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2018 | 2 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Studies
Open first, then newest update. How each study uses vesleteplirsen is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Expansion (Part B) in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping TreatmentTerminatedPhase 2Sarepta Therapeutics, Inc.NCT04004065Written as Vesleteplirsen
- An Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy Who Participated in Studies of SRP-5051 (Vesleteplirsen)TerminatedPhase 1/2Sarepta Therapeutics, Inc.NCT03675126Written as SRP-5051
- A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 (Vesleteplirsen) in Patients With Duchenne Muscular Dystrophy (DMD)CompletedPhase 1Sarepta Therapeutics, Inc.NCT03375255Written as SRP-5051
Codes
What other systems call vesleteplirsen · ClinicalTrials.gg INT016527
- UNII (FDA) F6U7EZ3N1QVESLETEPLIRSENOne source FDA
- NCI Thesaurus C184817VesleteplirsenOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | F6U7EZ3N1Q | VESLETEPLIRSEN | One source FDA |
| NCI Thesaurus | C184817 | Vesleteplirsen | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.